601512-79-2

Upstream product

• 128114-97-6 1-(3-deoxy-2-fluoro-5-O-trityl-β-D-arabinofuranosyl)thymine 
• 601512-75-8 1-O-acetyl-2-deoxy-2-fluoro-3,5-di-O-benzoyl-α,β-D-xylofuranose 
• 7288-28-0 2,4-bis(trimethylsiloxy)-5-methylpyrimidine 
• 28279-75-6 methyl 2-deoxy-3,5-di-O-benzoyl-2-fluoro-β-D-xylofuranoside 
• 65-71-4 thymin 
• 601512-77-0 C₂₄H₂₁FN₂O₇ 

Downstream Products

• 601512-80-5 1-[2-deoxy-5-O-(4,4'-dimethoxytrityl)-2-fluoro-β-D-xylofuranosyl]thymine 

Relevant academic research and scientific papers

xylo-configured oligonucleotides (XNA, xylo nucleic acids): Synthesis and hybridization studies

We report synthesis and high-affinity hybridization of fully modified home-thymine 2′-deoxy and 2′-deoxy-2′-fluoro xylo nucleic acids.

MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF

The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard nucleoside. An oligomeric compound comprising a modified oligonucleotide consisting of 12-30 linked nucleosides, wherein at least one nucleoside of the modified oligonucleotide is a stereo-non-standard nucleoside; and wherein the oligomeric compound is selected from among an RNAi compound, a modified CRISPR compound, and an artificial mRNA compound.

MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF

The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard nucleoside.

Antiviral activity of various 1-(2′-Deoxy-β- d -lyxofuranosyl), 1-(2′-Fluoro-β- d -xylofuranosyl), 1-(3′-Fluoro-β- d -arabinofuranosyl), and 2′-fluoro-2′,3′-didehydro-2′, 3′-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and human hepatitis B virus (HBV) replication

Despite the existence of successful vaccine and antiviral therapies, infection with hepatitis B virus (HBV) continues to be a major global cause of acute and chronic liver disease and high mortality. We synthesized and evaluated several lyxofuranosyl, 2′-fluoroxylofuranosyl, 3′- fluoroarabinofuranosyl, and 2′-fluoro-2′,3′-didehydro- 2′,3′-dideoxyribose pyrimidine nucleoside analogues for antiviral activities against hepatitis B virus. Among the compounds examined, 1-(2-deoxy-β-d-lyxofuranosyl)thymine (23), 1-(2-deoxy-β-d- lyxofuranosyl)-5-trifluoromethyluracil (25), 1-(2-deoxy-2-fluoro-β-d- xylofuranosyl)uracil (38), 1-(2-deoxy-2-fluoro-β-d-xylofuranosyl)thymine (39), 2′,3′-dideoxy-2′,3′-didehydro-2′- fluorothymidine (48), and 2′,3′-dideoxy-2′,3′-didehydro- 2′-fluoro-5-ethyluridine (49) were found to possess significant anti-HBV activity against DHBV in primary duck hepatocytes with EC50 values of 4.1, 3.3, 40.6, 3.8, 0.2, and 39.0 μM, respectively. Compounds 23, 25, 39, 48, and 49 (EC50 = 41.3, 33.7, 19.2, 2.0-4.1, and 39.0 μM, respectively) exhibited significant activity against wild-type human HBV in 2.2.15 cells. Intriguingly, 25, 39, 48, and 49 retained sensitivity against lamivudine-resistant HBV containing a single mutation (M204I) and 48 emerged as an effective inhibitor of drug-resistant HBV with an EC50 of 4.1 μM. In contrast, 50% inhibition could not be achieved by lamivudine at 44 μM concentration in the drug-resistant strain. The compounds investigated did not show cytotoxicity to host cells up to the highest concentrations tested.

XNA ?(xylo nucleic acid): A summary and new derivatives

Fully modified homopyrimidine 2′-deoxy-xylo nucleic acid (dXNA) form triple helixes with complementary DNA/RNA with thermal stabilities comparable to those of the corresponding DNA:DNA and DNA:RNA duplexes. However, a single or few insertions of dXNA monomers in a DNA strand significantly lower duplex stabilities. The dXNA monomers are known to adopt predominantly an N-type furanose conformation in solution. With a desire to increase the binding affinity, seven sugar-modified XNA monomers (H, F, N, M, K, P and Q) have been synthesised and their effect on hybridization towards DNA and RNA complements studied. The introduction of 2′-fluoro and 2′-hydroxy substituents was expected to induce conformational restriction towards C3′-endo-type furanose conformation of monomer F derived from 1-(2′-deoxy-2′-fluoro-β-D-xylofuranosyl)thymine and monomer H derived from 1-(β-D-xylofuranosyl)thymine. The presence of functionalites facing the minor groove as in 1-(2′-amino-2′-deoxy-2′-N, 4′-C-methylene-β-D-xylofuranosyl)thymine (monomer N), 1-[4-C-(N-methylpiperazinyl)methyl-β-D-xylofuranosyl]thymine (monomer P), 1-(4-C-piperazinylmethyl-β-D-xylofuranosyl)thymine (monomer Q), 1-(4-C-hydroxymethyl-β-D-xylofuranosyl)thymine (monomer M) and 9-(4-C-hydroxymethyl-β-D-xylofuranosyl)adenine (monomer K) was studied, with monomer N being locked in an N-type furanose conformation. Besides, an efficient synthesis of known xylo-LNA phosphoramidite 19, required for the incorporation of 1-(2′-O,4′-C-methylene-β-D-xylofuranosyl)thymine (monomer L) is described. For comparison, hydridization data of various XNAs reported in the literature are included in the discussion section. The thermal denaturation studies show that XNAs containing conformationally locked monomers (N and L) display improved binding affinity, and that partially modified DNA/XNA chimera, or fully modified XNA display preferential hybridization towards RNA complements. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005.

Xylo-configured oligonucleotides (XNA, xylo nucleic acid): Synthesis of conformationally restricted derivatives and hybridization towards DNA and RNA complements

Xylo-Configured oligonucleotides (XNA) containing a novel conformationally restricted 2′-deoxy-2′-fluoro-β-D-xylofuranosyl nucleotide monomer, a novel conformationally locked 2′-amino-2′-deoxy-2′-N,4′-C-methylene-β-D- xylofuranosyl nucleotide monomer, and